Xeris Biopharma Holdings (XERS) Non-Current Debt (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Non-Current Debt came in at $221.2 million in Q1 2026, down 3.72% YoY from $229.8 million in Q1 2025, and little changed on a QoQ basis from $220.3 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Non-Current Debt (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Non-Current Debt data on file, last reported at $221.2 million in Q1 2026.
- Quarterly Non-Current Debt fell 3.72% year-over-year to $221.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.2 million (down 3.72% YoY) and the FY2025 annual result came in at $220.3 million, down 5.07% from the prior year.
- Non-Current Debt steadied at $221.2 million in Q1 2026, from $220.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $232.1 million in Q4 2024 to a low of $137.6 million in Q1 2022.
- A 5-year average of $198.6 million and a median of $216.2 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 112.42% — and 2025, when it decreased 5.14%.
- Tracing XERS's Non-Current Debt over 5 years: stood at $187.1 million in 2022, then rose by 2.06% to $190.9 million in 2023, then gained by 21.57% to $232.1 million in 2024, then declined by 5.07% to $220.3 million in 2025, then advanced by 0.4% to $221.2 million in 2026.
- The last three Non-Current Debt figures came in at $221.2 million (Q1 2026), $220.3 million (Q4 2025), and $219.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 252.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 252.59 Mn |
| Mar 31, 2026 | 221.22 Mn |
| Dec 31, 2025 | 220.34 Mn |
| Sep 30, 2025 | 219.47 Mn |
| Jun 30, 2025 | 218.63 Mn |
| Mar 31, 2025 | 229.76 Mn |
| Dec 31, 2024 | 232.11 Mn |
| Sep 30, 2024 | 216.23 Mn |
| Jun 30, 2024 | 230.48 Mn |
| Mar 31, 2024 | 229.67 Mn |
| Dec 31, 2023 | 190.93 Mn |
| Sep 30, 2023 | 190.42 Mn |
| Jun 30, 2023 | 188.18 Mn |
| Mar 31, 2023 | 187.62 Mn |
| Dec 31, 2022 | 187.08 Mn |
| Sep 30, 2022 | 138.51 Mn |
| Jun 30, 2022 | 138.07 Mn |
| Mar 31, 2022 | 137.64 Mn |
| Dec 31, 2021 | 88.07 Mn |
| Sep 30, 2021 | 87.71 Mn |